We report the gene expression profile in BRCA deficient tumors after treatment with saline, nanoparticle-formulated Talazoparib and free Talazoparib Overall design: To study the regulation of gene exp

NIAID Data Ecosystem30

DataSheet2_The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.xlsx

同源重组修复缺陷

PARP抑制剂反应

Background: Gene-agnostic genomic biomarkers were recently developed to identify homologous recombination deficiency (HRD) tumors that are likely to respond to treatment with PARP inhibitors. Two mach

NIAID Data Ecosystem20

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

癌症生物标志物

PARP抑制剂反应

Germline mutations in BRCA1 or BRCA2 exist in approximately 7% of patients diagnosed with breast cancer and are associated with defects in homologous recombination repair, which has led to the approva

NIAID Data Ecosystem30

Genotyping frequencies and the association of genotype with disease progression during ADT.

前列腺癌精准治疗

基因型-表型关联分析

Abbreviations: ADT, androgen-deprivation therapy; HR, hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen. *P values were calculated using the log-rank test. †HRs were adjust

NIAID Data Ecosystem20

CRISRP screens reveal determinants of PARP inhibitor response in prostate cancer

资源简介：

相关数据集